

Product Sheet

CMV Primer ASR

Contents

CMV DNA primer (28.9 μ M of forward primer and 43.4 μ M of reverse primer) 2 x 18 μ l in buffered solution

Description

Analyte Specific Reagent. Analytical and performance characteristics are not established.

The CMV Primer ASR (cat. no. 1124260) contains a specific nucleic acid sequence for the amplification of cytomegalovirus (CMV). The CMV Primer ASR is designed to detect a 105 bp region of the MIE gene in the CMV genome. The DNA is synthetically derived.

Storage conditions

Upon receipt, store the CMV Primer ASR at -30 to -15°C . Repeated thawing and freezing ($> 2\times$) should be avoided, as this may reduce reagent performance. If the reagents are to be used intermittently, they should be frozen in aliquots. Storage at $2-8^{\circ}\text{C}$ should not exceed a period of 5 hours.

Handling instructions

Store the CMV Primer ASR away from any source of contaminating DNA, especially amplified DNA products. Use aerosol-barrier pipet tips for pipetting the CMV Primer ASR.

Quality Control

This product was manufactured and released in accordance with the QIAGEN GmbH, Hilden, Quality Control and Quality Assurance procedures. The product has met QIAGEN GmbH, Hilden, quality requirements. Purity of the synthetic oligonucleotide is >80%, as determined by high-performance liquid chromatography (HPLC).

Safety Information

When working with chemicals, always wear a suitable lab coat, disposable gloves, and protective goggles. For more information, please consult the appropriate safety data sheets (SDSs). These are available online in convenient and compact PDF format at www.qiagen.com/safety, where you can find, view, and print the SDS for each QIAGEN kit and kit component.

Dispose of in accordance with local regulations.

Ordering Information

Product	Contents	Cat. no.
CMV Primer ASR	CMV DNA primer in buffered solution	1124260

Document Revision History

Date	Changes
R1, April 2021	Initial release.

Trademarks: QIAGEN®, Sample to Insight® (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

1124545 04/2021 HB-2910-001 © 2021 QIAGEN, all rights reserved.